Glycotargeting therapeutics

Patent metadata

Field	Value
Publication number	US-10046056-B2
Application number	US-201615185564-A
Country	US
Kind code	B2
Filing date	Jun 17, 2016
Priority date	Feb 21, 2014
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

First claim

What is claimed is:

1. A composition comprising a compound of Formula 1:
X Y—Z]L   Formula 1

where:
m is an integer from about 1 to 100;
X comprises an antigen against which a patient develops an unwanted immune response;
Y comprises

where:
the left bracket “(” indicates the bond between X and Y;
the bottom bracket and “)” indicates the bond between Y and Z;
n is an integer from about 1 to 100;
R 9 is —CH 2 — or —CH 2 —CH 2 —C(CH 3 )(CN)—; and
W represents a polymer of the same W 1 group, or W is a copolymer or a random copolymer of the same or different W 1 and W 2 groups, where:

where:
p is an integer from 2 to about 150;
R 9 is a direct bond, —C(O)—NH—CH 2 —CH 2 —, or —C(O)—NH—(CH 2 —CH 2 —O—) t —CH 2 —CH 2 —;
t is an integer from 1 to 5; and
R 10 is an aliphatic group, an alcohol or an aliphatic alcohol; and

Z comprises one or more liver-targeting moieties.

2. The composition of claim 1 where Z comprises galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine.

3. The composition of claim 2 , wherein Z is the beta anomer.

4. The composition of claim 2 comprising Z conjugated at its C1, C2 or C6 to Y.

5. The composition of claim 1 where Y is prepared using a linker precursor selected from N-hydroxysuccinamidyl-based linkers, malaemide-based linkers, vinylsulfone-based linkers, pyridyl di-thiol-poly(ethylene glycol)-based linkers, pyridyl di-thiol-based linkers, n-nitrophenyl carbonate-based linkers, NHS-ester-based linkers, and nitrophenoxy poly(ethylene glycol)ester-based linkers.

6. The composition of claim 1 , wherein X is a synthetic self-antigen and the unwanted immune response is an autoimmune response.

7. The composition of claim 1 , wherein X is selected from the group consisting of myelin oligodendrocyte glycoprotein, myelin proteolipid protein, and myelin basic protein and wherein the unwanted immune response is associated with multiple sclerosis.

8. The composition of claim 1 , wherein X is selected from the group consisting of insulin, proinsulin, and preproinsulin and wherein the unwanted immune response is associated with type 1 diabetes mellitus.

9. The composition of claim 1 , wherein X is a therapeutic agent selected from the group consisting of Factor VIII and Factor IX.

10. The composition of claim 1 , wherein X is a therapeutic agent selected from the group consisting of asparaginase and uricase.

11. The composition of claim 1 , wherein X is a is a food antigen selected from the group consisting of: conarachin (Ara h 1), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), a-lactalbumin (ALA), lactotransferrin, Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform, high molecular weight glutenin, low molecular weight glutenin, alpha-gliadin, gamma-gliadin, omega-gliadin, hordein, secalin, and avenin.

12. The composition of claim 1 , wherein administration of the composition to the subject results in a greater degree of proliferation of antigen-specific T cells as compared to proliferation of antigen-specific T cells resulting from administration of the antigen alone.

13. The composition of claim 3 , wherein administration of the composition to the subject results in a greater expression of exhaustion markers or markers of apoptosis on antigen-specific T cells as compared to expression of exhaustion markers or markers of apoptosis on antigen-specific T cells resulting from administration of the antigen alone.

14. A composition for inducing tolerance to an antigen to which a subject develops an unwanted immune response, the composition comprising a compound of Formula 1:
X Y—Z]L   Formula 1

where:
m is an integer from about 1 to 10;
X comprises an antigen to which patients develop an unwanted immune response, wherein the antigen is a food antigen, a therapeutic agent, or a self-antigen;
Y is:

wherein:
the left bracket “(” indicates a bond to X;
the bottom bracket and “)” indicates the bond between Y and Z;
n is an integer from about 1 to 100;
R 8 is —CH 2 —CH 2 —C(CH 3 )(CN)—;
W represents a polymer of the same W 1 group, or W is a copolymer or a random copolymer of the same or different W 1 and W 2 groups, where:

where:
p is an integer from 2 to about 150;
where present R 9 is a direct bond, —C(O)—NH—CH 2 —CH 2 —, or —C(O)—NH—(CH 2 —CH 2 —O—) t —CH 2 —CH 2 —;
t is an integer from 1 to 5; and
R 10 is an aliphatic group, an alcohol, or an aliphatic alcohol; and
Z comprises one or more of galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N-acetyl glucosamine.

15. The composition of claim 14 , wherein m is 1 to 3.

16. The composition of claim 14 , wherein X is selected from the group consisting of myelin oligodendrocyte glycoprotein, myelin proteolipid protein, and myelin basic protein and wherein the unwanted immune response is associated with multiple sclerosis.

17. The composition of claim 14 , wherein X is a is a food antigen selected from the group consisting of: conarachin (Ara h 1), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), a-lactalbumin (ALA), lactotransferrin, Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform, high molecular weight glutenin, low molecular weight glutenin, alpha-gliadin, gamma-gliadin, omega-gliadin, hordein, secalin, and avenin.

18. The composition of claim 1 , wherein m is 1 to 3;
R 8 is —CH 2 —CH 2 —C(CH 3 )(CN)—;
R 9 is —C(O)—NH—(CH 2 —CH 2 —O—) t —CH 2 —CH 2 —;
t is 1;
R 10 is CH 2 CH 2 OH; and
Z comprises a liver-targeting moiety comprising one or more of galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, and N-acetylglucosamine.

19. The composition of claim 14 , wherein X is selected from the group consisting of insulin, proinsulin, and preproinsulin and wherein the unwanted immune response is associated with type 1 diabetes mellitus.

20. The composition of claim 14 , wherein X is a self-antigen and the unwanted immune response is an autoimmune response.

21. The composition of claim 14 , wherein Z is the beta anomer.

22. The composition of claim 14 comprising Z conjugated at its C1, C2 or C6 to Y.

23. The composition of claim 14 , wherein X is a therapeutic agent selected from the group consisting of Factor VIII and Factor IX.

24. The composition of claim 14 , wherein X is a therapeutic agent selected from the group consisting of asparaginase and uricase.

25. The composition of claim 14 , wherein m is 1 to 3;
R 9 is —CH 2 —CH 2 —(O—CH 2 —CH 2 ) t —NH—C(O)—;
t is 1; and
R 19 is CH 2 CH 2 OH.

Assignees

• Ecole Polytechnique Fed Lausanne Epfl

Inventors

• Hubbell Jeffrey A
• Wilson David Scott

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K39/35

  Allergens · CPC title

• A61K38/37

  Factors VIII · CPC title

• A61K38/28

  Insulins · CPC title

• C07K2317/55

  Fab or Fab' · CPC title